Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
This advancement could allow for assisted transport, making synthetic platelets a viable option in healthcare locations with limited resources, such as rural hospitals, ambulances, and battlefield settings. While preclinical results are encouraging, challenges remain in the large-scale clinical translation of synthetic platelets. Reproducibility, large-scale production, and safety issues must be addressed to gain regulatory approval and commercial viability. Researchers continue to refine synthetic platelet formulations by maximizing circulation time, stability, and biodegradability while minimizing undesirable immune responses. Additionally, studies have shown that synthetic platelets are excreted from the body within hours if they do not reach a wound site, which reduces the risk of unintended clotting in other parts of the body.
As a paramilitary unit, the BSAP fought in the Second Boer War and in German East Africa during the First World War, while some members were seconded to the Rhodesia Native Regiment. From 1923, Southern Rhodesia was a self-governing colony of the British Empire, but the BSAP retained its title and its position as the senior regiment of the Southern Rhodesian armed forces. One of the first casualties of the BSAP in the Second World War was Keppel Bagot Levett, born in 1919, who died in active service with the BSAP in March 1941. Between the World Wars, the Permanent Staff Corps of the Rhodesian Army consisted of only 47 men. The BSAP were trained as both policemen and soldiers until 1954.
=== Death of Asa Gilbert Eddy === Eddy's husband, Asa Gilbert Eddy, died of heart disease on June 4, 1882, shortly after the move to Boston. She invited the Boston Globe to her home on the day of his death to allege that he had been killed by malicious animal magnetism, courtesy of "certain parties here in Boston, who had sworn to injure them." The Globe wrote:
Little is known about Crystal's background, other than her mother forcing her to leave home at 16 and that she married at 17, shortly after graduating high school, only to be widowed at 18. Although Crystal still mourns Sonny's death, she acknowledges that she always knew he was cheating on her. Crystal speaks with a Southern accent despite being a Lanford native; her explanation is that her father was from Arkansas.
Sources: en.wikipedia.org
The expansion of Toronto in the east, in the 19th century, led to the development of housing stock along the Kingston Road and Danforth Road corridors in Scarborough. This led to the creation of a transit line. In 1893, the Toronto and Scarboro' Electric Railway, Light and Power Company built a single-track radial line along Kingston Road to Blantyre. Over the next 13 years this was extended to West Hill. In 1904, the line became the Scarboro Division of the Toronto and York Radial Railway. Service continued along this line until 1936 when it was replaced by bus service.
Dextran micelles are 10 to 100 nm sized amphiphilic polymeric particles which have the advantages of avoiding drug clearance by the kidneys and traveling through blood vessels. The core of these micelles are hydrophobic, allowing for loading of hydrophobic drugs into the micelle. The outer shell of the particles is hydrophilic, which allows for long circulation times in the blood. Dextran can be conjugated with other materials to form polymeric micelles including stearic acid and cholesterol to further improve sustained release of the loaded hydrophobic drug. The size of the micelles can be controlled by altering the ratio of stearic acid to dextran. Dextran micelles can also be formed from conjugation with polycaprolactone, folic acid, retinoic acid, and PLGA.
Genetic or syndromic gingival enlargement, such as Zimmermann-Laband or Ramon syndrome, presents as firm, fibrotic, and persistent nodular gingival overgrowth that usually begins around tooth eruption. Systemic or hormonal causes, including pregnancy, hormonal imbalance, leukemia, granulomatosis with polyangiitis (strawberry gingivitis), and vitamin C deficiency, can also result in gingival enlargement. In rare cases, gingival enlargement may be neoplastic, such as in squamous cell carcinoma or fibroma. Clinically, gingival enlargement often obscures the CEJ, and the gingival margin appears coronally positioned. Unlike CAL, gingival enlargement is often reversible or manageable once the underlying cause is addressed, though surgical correction may be required in fibrotic or genetic cases.
=== Beyond Raw === GNC is a company that offers creatine supplements in both pill and powder forms through its GNC AMP® and Beyond Raw® Chemistry Labs product lines. Their products have been scientifically supported and clinically tested, such as the GNC AMP® Creatine HCl 189™. In collaboration with The Hershey Company, products like Beyond Raw® LIT™ JOLLY RANCHER Grape pre-workout powder and on the-go have been produced which come in flavours like watermelon, green apple, and blue raspberry. Each pre-workout supplement contains clinically dosed ingredients, such as L-Citrulline, CarnoSyn betaalanine, micronized creatine, caffeine, and Nitrosigine. Other supplements like Burn MF Metabolic Activator Powder, Capsules, Sticks, and Drink belong to the Beyond Raw brand. Additionally, the text mentions that a new flavor, JOLLY RANCHER Grape, has been launched after the release of another supplement called Beyond Raw Concept X in May 2022. However, in a settlement with the Department of Justice, GNC, the largest retailer of supplements in the country, has agreed to pay $2.25 million. This settlement comes as part of a larger effort by the federal government to crack down on supplements that contain undisclosed drug ingredients, harmful compounds, or inaccurate ingredient labeling. As part of the settlement, GNC has committed to improving its product screening process and removing any supplements containing illegal or unsafe ingredients. In addition, the company will maintain a list of products that have been deemed safe for sale.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.